Evolution of therapy for limited stage diffuse large B-cell lymphoma

Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma (NHL), with limited-stage DLBCL defined as stage I or II disease. Risk stratification, initial treatment options, and relapse patterns are distinct from advanced-stage DLBCL, but there is limited data on the impact of biol...

Descripción completa

Detalles Bibliográficos
Autores principales: Rojek, Alexandra E., Smith, Sonali M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8867133/
https://www.ncbi.nlm.nih.gov/pubmed/35210407
http://dx.doi.org/10.1038/s41408-021-00596-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8867133/
https://www.ncbi.nlm.nih.gov/pubmed/35210407
http://dx.doi.org/10.1038/s41408-021-00596-z

Ejemplares similares